CClinicalTrials.gg
Active, not recruitingNCT06592001ASCEND EVUpdated Dec 4, 2025

Assessment of a Chronically Implanted Parasternally Delivered EV-ICD Lead (ASCEND EV) Study

An interventional study of Atala™ lead in Ventricular Arrythmia, Ventricular Fibrillation and Ventricular Tachycardia, sponsored by AtaCor Medical, Inc.. Active, not recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by AtaCor Medical, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The ASCEND EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of the study is to evaluate the Investigational Devices through at least 3-months of follow-up to inform the design of a subsequent pivotal clinical investigation.

The objectives of the study are to: 1) preliminarily validate safety and effectiveness of the Atala™ lead as a permanent ICD lead when used with a compatible ICD pulse generator, 2) evaluate suitability of clinical study testing methods and 3) inform statistically powered primary safety and effectiveness endpoints in a subsequent pivotal clinical investigation.

Read the detailed description

The primary safety endpoint is freedom from major Adverse Device Effects (ADEs) through 3-months. The primary performance endpoint is successful induced ventricular arrhythmia (IVA) test in the final system configuration.

Up to three (3) Investigational Sites will participate with up to 35 Subjects enrolled in the study. Subjects who meet current indications for ICD therapy will be eligible for participation. Eligible Subjects will receive an Atala™ lead connected to a commercially available ICD positioned in a left pectoral or left lateral location.

The Atala™ lead will be connected to a compatible ICD pulse generator and tested to verify appropriate sensing and defibrillation. Abbreviated IVA testing will be performed at the 3-month follow-up visit to verify continued sensing and defibrillation effectiveness. Starting at 6 months, Subjects will be followed every 6 months until the study is closed. The study is expected to remain open for at least 3 years.

Endpoints will be analyzed and summarized in a final study report after all active Subjects have completed the 3-month visit.

02

Conditions studied

  • Ventricular Arrythmia
  • Ventricular Fibrillation
  • Ventricular Tachycardia

Keywords

  • Ventricular Defibrillation
  • Extravascular
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. At least 18 years old
  2. Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines or ESC guidelines

Exclusion criteria

Exclusion Criteria:

  1. Participation in any concurrent clinical study without prior written approval from the Sponsor
  2. Inability or unwillingness to provide informed consent to participate in the Study
  3. Any known conditions which may complicate the AtaCor EV-ICD Lead System implant procedure or prevent the subject from completing protocol testing through the 3-month follow-up visit
  4. Circumstances that may prevent data collection or completion of specified follow-up visits
  5. Allergies to any device materials listed in the Instructions for Use (IFU)
  6. Subjects on anticoagulation therapy that cannot be temporarily discontinued for the procedure
  7. Known history of lung disease with FEV1 \< 1.0 Liter

    Device Related:

  8. Presence or planned use of medical devices that introduce current into the body (e.g., pacemaker, LVAD, neurostimulator, etc.)
  9. Implanted with or planned implantation of any device which delivers current in the body, that may interfere with therapy delivery, including, but not limited to a pacemaker, or neurostimulator
  10. Presence or planned use of a subcutaneous ICD lead, subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads
  11. Any known need for future MRI

    Anatomy Related:

  12. BMI ≥ 35 kg/m2
  13. Structural abnormalities of the heart that may increase risk of the study procedure or an obstructed/restricted pathway into the mediastinum
  14. Prior sternotomy of any type, including but not limited to median, mini or clamshell
  15. Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium
  16. Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis) and associated with displacement of the heart or lungs or impeded mediastinal access.
  17. History of thoracic radiation therapy, pneumothorax, pneumomediastinum or other medical treatments/conditions which may complicate the AtaCor EV-ICD Lead System implant procedure
  18. Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax
  19. Surgically corrected congenital heart disease (not including catheter-based procedures)

    Cardiac Related:

  20. Subjects who require permanent bradycardia pacing or cardiac resynchronization therapy
  21. NYHA IV functional class in past 90 days
  22. Inotropic therapy in past 180 days
  23. Known history of pericardial disease, pericarditis or mediastinitis
  24. Patients with a medical condition that precludes them from undergoing defibrillation testing:

    • Severe aortic stenosis
    • Current Intracardiac LA or LV thrombus
    • Severe proximal three-vessel or left main coronary artery disease without revascularization
    • Hemodynamic instability
    • Unstable angina
    • Recent stroke or transient ischemic attack (within the last 6 months)
    • Known inadequate external defibrillation
    • LVEF \< 20%
    • LVEDD >70 mm
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    AtaCor EV-ICD Lead System

    Subjects implanted with the Atala™ lead

    Device: Atala™ lead

Interventions

  • DeviceAtala™ lead

    Subjects will receive the Atala™ lead being evaluated in the study.

    Also known as: AtaCor EV-ICD Atala™ lead, AtaCor Atala™ lead

05

What researchers measure

Primary outcomes

  1. Freedom from major ADEs

    Freedom from major Adverse Device Effects (ADEs)

    Time frame: Through 3 months post-implant

  2. Successful IVA Test

    Successful induced ventricular arrhythmia (IVA) test in the final system configuration

    Time frame: At the time of procedure

06

Study locations

3 sites
  • University Hospital Center Split
    Split, 21000, Croatia
  • Christchurch Hospital
    Christchurch, New Zealand
  • Sanatorio Italiano
    Asunción, Paraguay
07

Registry details

Key details

Study ID
NCT06592001
Lead sponsor
AtaCor Medical, Inc.
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Feb 25, 2025
Primary completion
Oct 27, 2025
Completion
Dec 31, 2028 (estimated)
Last update
Dec 4, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion